Orchestra BioMed (NASDAQ:OBIO) Announces Earnings Results, Beats Estimates By $0.10 EPS

Orchestra BioMed (NASDAQ:OBIO) released its earnings results on Tuesday. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10, FiscalAI reports. Orchestra BioMed had a negative net margin of 184.60% and a negative return on equity of 149.61%. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.13 million.

Orchestra BioMed Stock Performance

Orchestra BioMed stock traded up $0.03 on Tuesday, hitting $5.73. The company’s stock had a trading volume of 485,538 shares, compared to its average volume of 291,705. Orchestra BioMed has a one year low of $3.46 and a one year high of $6.50. The firm has a market cap of $344.37 million, a P/E ratio of -6.74 and a beta of 0.56. The company has a quick ratio of 8.24, a current ratio of 8.26 and a debt-to-equity ratio of 1.80. The company has a fifty day moving average price of $5.75 and a 200-day moving average price of $4.58.

Insider Buying and Selling at Orchestra BioMed

In related news, insider Darren Sherman sold 15,000 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $4.94, for a total value of $74,100.00. Following the completion of the transaction, the insider owned 1,134,402 shares of the company’s stock, valued at $5,603,945.88. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Pacitti purchased 20,000 shares of the business’s stock in a transaction on Monday, November 9th. The shares were acquired at an average price of $5.00 per share, with a total value of $100,000.00. Following the purchase, the director owned 74,750 shares of the company’s stock, valued at approximately $373,750. This trade represents a 36.53% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 58,000 shares of company stock valued at $288,560 and sold 45,000 shares valued at $255,600. Company insiders own 7.50% of the company’s stock.

Key Stories Impacting Orchestra BioMed

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: The company completed enrollment in the global pivotal BACKBEAT trial, randomizing 349 patients—above its enrollment target. It plans to submit primary-endpoint results for a late-breaking presentation at the Heart Rhythm Society’s 2027 meeting, bringing a significant clinical update closer. Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
• Positive Sentiment: Company insiders and directors, including David Hochman, CFO Andrew Taylor, and directors David Pacitti and Eric Fain, bought shares at $5.00 each. Such purchases may signal confidence, though they do not guarantee future performance. Orchestra BioMed Insider Purchases
• Neutral Sentiment: Quarterly loss per share was $0.30, better than analysts’ $0.40 estimate. Revenue of $0.09 million, however, came in below the $0.13 million consensus. Third Quarter 2026 Results
• Negative Sentiment: Orchestra BioMed remains unprofitable, with a reported negative net margin and return on equity, underscoring its ongoing financial risk as it advances clinical programs.

Analysts Set New Price Targets

Several analysts have issued reports on OBIO shares. Piper Sandler restated an “overweight” rating on shares of Orchestra BioMed in a research report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research report on Monday, October 5th. Weiss Ratings upgraded shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Friday, October 23rd. Finally, B. Riley Financial boosted their price target on Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization. Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.